Logo image of IONS

IONIS PHARMACEUTICALS INC (IONS) Stock Fundamental Analysis

NASDAQ:IONS - Nasdaq - US4622221004 - Common Stock - Currency: USD

37.19  +0.18 (+0.49%)

Fundamental Rating

3

Overall IONS gets a fundamental rating of 3 out of 10. We evaluated IONS against 557 industry peers in the Biotechnology industry. The financial health of IONS is average, but there are quite some concerns on its profitability. IONS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IONS had negative earnings in the past year.
IONS had a negative operating cash flow in the past year.
IONS had negative earnings in each of the past 5 years.
In multiple years IONS reported negative operating cash flow during the last 5 years.
IONS Yearly Net Income VS EBIT VS OCF VS FCFIONS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

With an excellent Return On Assets value of -16.28%, IONS belongs to the best of the industry, outperforming 80.25% of the companies in the same industry.
IONS has a Return On Equity (-96.28%) which is in line with its industry peers.
Industry RankSector Rank
ROA -16.28%
ROE -96.28%
ROIC N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
IONS Yearly ROA, ROE, ROICIONS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 98.53%, IONS belongs to the top of the industry, outperforming 98.38% of the companies in the same industry.
In the last couple of years the Gross Margin of IONS has remained more or less at the same level.
IONS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
IONS Yearly Profit, Operating, Gross MarginsIONS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

4

2. Health

2.1 Basic Checks

IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IONS has more shares outstanding
IONS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IONS has been reduced compared to a year ago.
IONS Yearly Shares OutstandingIONS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
IONS Yearly Total Debt VS Total AssetsIONS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 0.95, we must say that IONS is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.95, IONS is doing good in the industry, outperforming 66.43% of the companies in the same industry.
A Debt/Equity ratio of 2.63 is on the high side and indicates that IONS has dependencies on debt financing.
With a Debt to Equity ratio value of 2.63, IONS is not doing good in the industry: 82.23% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.63
Debt/FCF N/A
Altman-Z 0.95
ROIC/WACCN/A
WACC7.55%
IONS Yearly LT Debt VS Equity VS FCFIONS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

IONS has a Current Ratio of 9.66. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 9.66, IONS is in the better half of the industry, outperforming 77.20% of the companies in the same industry.
IONS has a Quick Ratio of 9.62. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
IONS's Quick ratio of 9.62 is fine compared to the rest of the industry. IONS outperforms 76.84% of its industry peers.
Industry RankSector Rank
Current Ratio 9.66
Quick Ratio 9.62
IONS Yearly Current Assets VS Current LiabilitesIONS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for IONS have decreased strongly by -11.99% in the last year.
IONS shows a decrease in Revenue. In the last year, the revenue decreased by -7.64%.
The Revenue has been decreasing by -8.88% on average over the past years.
EPS 1Y (TTM)-11.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.1%
Revenue 1Y (TTM)-7.64%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%10.92%

3.2 Future

IONS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.70% yearly.
IONS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.10% yearly.
EPS Next Y-6.51%
EPS Next 2Y-0.58%
EPS Next 3Y14.37%
EPS Next 5Y25.7%
Revenue Next Year19.72%
Revenue Next 2Y19.3%
Revenue Next 3Y24.13%
Revenue Next 5Y29.1%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IONS Yearly Revenue VS EstimatesIONS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
IONS Yearly EPS VS EstimatesIONS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IONS. In the last year negative earnings were reported.
Also next year IONS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IONS Price Earnings VS Forward Price EarningsIONS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IONS Per share dataIONS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

IONS's earnings are expected to grow with 14.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.58%
EPS Next 3Y14.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IONS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (6/20/2025, 2:48:45 PM)

37.19

+0.18 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners107.04%
Inst Owner Change2.53%
Ins Owners0.81%
Ins Owner Change11.72%
Market Cap5.92B
Analysts80
Price Target58.71 (57.87%)
Short Float %9.56%
Short Ratio9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.37%
Min EPS beat(2)18.36%
Max EPS beat(2)42.39%
EPS beat(4)4
Avg EPS beat(4)33.09%
Min EPS beat(4)18.36%
Max EPS beat(4)52.1%
EPS beat(8)8
Avg EPS beat(8)33.95%
EPS beat(12)10
Avg EPS beat(12)22.81%
EPS beat(16)13
Avg EPS beat(16)43.75%
Revenue beat(2)2
Avg Revenue beat(2)32.49%
Min Revenue beat(2)3.26%
Max Revenue beat(2)61.73%
Revenue beat(4)4
Avg Revenue beat(4)28.28%
Min Revenue beat(4)0.96%
Max Revenue beat(4)61.73%
Revenue beat(8)7
Avg Revenue beat(8)27.53%
Revenue beat(12)9
Avg Revenue beat(12)18.05%
Revenue beat(16)11
Avg Revenue beat(16)16.69%
PT rev (1m)-0.6%
PT rev (3m)-2.73%
EPS NQ rev (1m)6.73%
EPS NQ rev (3m)46.44%
EPS NY rev (1m)0%
EPS NY rev (3m)16.27%
Revenue NQ rev (1m)3.27%
Revenue NQ rev (3m)79.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.25
P/FCF N/A
P/OCF N/A
P/B 12.44
P/tB 12.44
EV/EBITDA N/A
EPS(TTM)-2.99
EYN/A
EPS(NY)-3.08
Fwd EYN/A
FCF(TTM)-3.49
FCFYN/A
OCF(TTM)-3.15
OCFYN/A
SpS4.51
BVpS2.99
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.28%
ROE -96.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.53%
FCFM N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
F-Score2
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 2.63
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 245.51%
Cap/Sales 7.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.66
Quick Ratio 9.62
Altman-Z 0.95
F-Score2
WACC7.55%
ROIC/WACCN/A
Cap/Depr(3y)135.24%
Cap/Depr(5y)139.85%
Cap/Sales(3y)4.04%
Cap/Sales(5y)3.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.1%
EPS Next Y-6.51%
EPS Next 2Y-0.58%
EPS Next 3Y14.37%
EPS Next 5Y25.7%
Revenue 1Y (TTM)-7.64%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%10.92%
Revenue Next Year19.72%
Revenue Next 2Y19.3%
Revenue Next 3Y24.13%
Revenue Next 5Y29.1%
EBIT growth 1Y-22.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.58%
EBIT Next 3Y19.87%
EBIT Next 5YN/A
FCF growth 1Y-38.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.21%
OCF growth 3YN/A
OCF growth 5YN/A